| Values | |
|---|---|
| Mean | 70 |
| Standard deviation | 8.9 |
| Median | 71 |
| Interquartile range | 11.5 |
| Mininum | 48 |
| Maximum | 87 |


| No. Cases (%) | |
|---|---|
| Male | 60 (61) |
| Female | 39 (39) |

| No. Cases (%) | |
|---|---|
| Pelvis | 45 (45) |
| Ureter | 50 (51) |
| Pelvis-ureter | 4 (4) |

| No. Cases (%) | |
|---|---|
| pTa | 19 (19) |
| pT1 | 18 (18) |
| pT2 | 8 (8) |
| pT3 | 48 (48) |
| pT4 | 6 (6) |

| No. Cases (%) | |
|---|---|
| Low pT (pT0-pT2) | 45 (45) |
| High pT (pT3-pT4) | 54 (55) |

| No. Cases (%) | |
|---|---|
| Grade 1 | 7 (7) |
| Grade 2 | 39 (39) |
| Grade 3 | 53 (54) |

| No. Cases (%) | |
|---|---|
| Low grade | 15 (15) |
| High grade | 84 (85) |

| No. Cases (%) | |
|---|---|
| No Lymph node metastasis | 84 (88) |
| Lymph node mestastasis | 12 (12) |

| No. Cases (%) | |
|---|---|
| No lymphovascular invasion | 59 (60) |
| Lymphovascular invasion | 40 (40) |

| Values | |
|---|---|
| Mean | 54.8 |
| Standard deviation | 39.9 |
| Median | 47 |
| Interquartile range | 56.5 |
| Mininum | 3 |
| Maximum | 173 |


| No. Cases (%) | |
|---|---|
| No tumor recurrence | 65 (67) |
| Tumor recurrence | 32 (33) |

| No. Cases (%) | |
|---|---|
| No tumor progression | 34 (41) |
| Tumor progression | 49 (59) |

| No. Cases (%) | |
|---|---|
| AWD | 5 (5) |
| DOC | 3 (3) |
| DOD | 30 (30) |
| LFU | 23 (23) |
| NED | 38 (38) |

| No. Cases (%) | |
|---|---|
| NED + AWD + LFU | 66 (67) |
| DOC + DOD | 33 (33) |
